Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $26.4 million.

  • Iovance Biotherapeutics' Net Cash Flow rose 14005.77% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year increase of 9650.02%. This contributed to the annual value of -$58.7 million for FY2024, which is 858.36% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Net Cash Flow of $26.4 million as of Q3 2025, which was up 14005.77% from -$40.4 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Net Cash Flow registered a high of $311.8 million during Q1 2023, and its lowest value of -$249.7 million during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Net Cash Flow had a median value of -$40.2 million in 2024 and averaged -$6.5 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 26578.09% in 2024, then surged by 23798.4% in 2025.
  • Iovance Biotherapeutics' Net Cash Flow (Quarter) stood at -$155.9 million in 2023, then skyrocketed by 69.63% to -$47.3 million in 2024, then soared by 155.7% to $26.4 million in 2025.
  • Its Net Cash Flow was $26.4 million in Q3 2025, compared to -$40.4 million in Q2 2025 and $55.5 million in Q1 2025.